Venture Life Group Executes Share Buyback of 46,716 Shares at 69.30p Each

Venture Life’s Consumer Healthcare Portfolio and Market Position

Venture Life Group plc operates internationally as a consumer self-care company with a focused portfolio of healthcare brands targeting specific health needs across multiple consumer segments. Its product lineup includes Balance Activ, a well-established brand in women’s intimate healthcare; Earol, supporting ear, nose, and throat care; the Lift and Glucogel ranges designed for energy management and hypoglycaemia treatment; and the Health & Her range addressing hormonal lifecycle support. These products are typically recommended by pharmacists and healthcare professionals, positioning the company within the professional-endorsed self-care segment rather than direct-to-consumer marketing.

Headquartered in the UK, Venture Life distributes products globally through multiple channels. In key markets such as the UK, Ireland, and the USA, the company supplies retailers directly. In other regions, it partners with established international distributors to reach end consumers. Distribution channels include health and beauty stores, pharmacies, grocery multiples, and e-commerce platforms, reflecting evolving retail trends and consumer buying behaviours. This omnichannel strategy ensures product availability and accessibility while managing inventory and logistics efficiently.

Share Buyback Programme Strategy and Capital Management

The share repurchase on 24 July 2026 is part of a wider capital management strategy initiated with the announcement of the share buyback programme on 30 September 2025. Such buybacks typically demonstrate management’s confidence in the company’s valuation, provide capital allocation flexibility, and can improve earnings per share by reducing share count. By retaining repurchased shares as treasury stock rather than cancelling them, Venture Life preserves options for future capital needs including employee share schemes, acquisitions, or further capital management activities. The timing and execution reflect management’s assessment of share price relative to intrinsic value.

The acquisition of 46,716 shares at a consistent volume weighted average price of 69.30 pence per share indicates disciplined execution by the company and its brokers. The exact match of the VWAP with both the lowest and highest price paid suggests the transaction occurred within a narrow trading band rather than opportunistically across a wide price range. Cavendish Capital Markets Limited, the company’s nominated adviser and broker, facilitated the transaction on the AIMX venue at 16:25 on 24 July 2026, adhering to standard market protocols for listed company share transactions.

Impact on Share Capital and Voting Rights

Post-buyback, Venture Life’s share capital totals 128,860,145 ordinary shares in issue, with 8,193,620 held as treasury shares. Treasury shares represent approximately 6.4% of total issued shares and reflect prior repurchase activity. Holding shares in treasury provides management and the board with capital flexibility for future corporate actions while mitigating immediate dilution risks from equity-based remuneration or other share issuances.

The total voting rights now stand at 120,666,525, excluding treasury shares which do not carry voting rights. Under FCA Disclosure Guidance and Transparency Rules, this voting rights figure serves as the denominator for shareholder notification thresholds. The reduction in voting rights due to treasury holdings may affect disclosure obligations for institutional investors holding fixed share quantities.

Transaction Execution and Trading Venue Details

The share buyback was completed in a single transaction on 24 July 2026 at 16:25, acquiring all 46,716 shares at a single price of 69.30 pence per share. The trade took place on the AIMX platform, the primary trading venue for AIM-listed securities. Executing the entire volume at one price contrasts with alternative strategies involving multiple tranches at varying prices over time.

Cavendish Capital Markets Limited, acting as nominated adviser and broker, managed the buyback execution. Their role includes advising the board on buyback appropriateness and ensuring efficient market execution in line with liquidity, trading volumes, and regulatory compliance. The transaction was promptly disclosed via an RNS announcement, providing transparency to market participants.

Treasury Shares and Future Capital Flexibility

By retaining the 46,716 repurchased shares as treasury stock rather than cancelling them, Venture Life maintains flexibility for future capital applications. Treasury shares remain part of issued share capital but carry no voting rights or dividends. Unlike cancellation, treasury shares can be reissued for new placements, employee share schemes, acquisition consideration, or cancelled at the board’s discretion.

The accumulated treasury holding of 8,193,620 shares offers significant optionality for management. Treasury shares can fund acquisitions without external capital raises, preserving shareholder value by avoiding dilution. They also support employee share plans such as Save-As-You-Earn or restricted awards without issuing new shares. This capital flexibility is valuable for growth-stage companies operating in dynamic markets requiring rapid capital deployment or incentive alignment.

Women’s Healthcare and Intimate Wellness Market Overview

Balance Activ, a core product in Venture Life’s portfolio, serves the women’s intimate healthcare segment—a substantial and growing area within consumer self-care. This category includes products supporting vaginal health, feminine hygiene, and wellness across lifecycle stages. Growth is driven by rising consumer awareness, destigmatisation of women’s health topics, and increased spending on preventative care.

Distribution primarily occurs through pharmacy channels where pharmacist recommendations strongly influence purchasing, alongside health and beauty retailers and growing e-commerce sales. The professional recommendation model creates stable demand compared to impulse-driven categories. Venture Life’s positioning of Balance Activ within this channel and global distribution reach enables it to capture expanding demand in multiple markets.

ENT Care and Specialty Health Products

Earol, the company’s ear, nose, and throat care brand, targets consumers seeking over-the-counter relief for common ENT conditions. This segment is stable and relatively recession-resistant, as demand for treatments addressing acute discomfort persists across economic cycles.

Pharmacy distribution is effective for ENT products, with pharmacists routinely recommending suitable options for ear discomfort, sinus issues, and related symptoms. Earol’s established pharmacy presence and direct retail supply in key markets support consistent availability and strong professional endorsement. Its specialty focus reduces exposure to intense price competition while maintaining steady demand.

Energy Management and Hypoglycaemia Support via Lift and Glucogel

The Lift and Glucogel ranges address glucose management and hypoglycaemia support, reflecting growing awareness of blood sugar control and metabolic health. Lift targets general energy management for wellness consumers, while Glucogel serves individuals managing diabetes or hypoglycaemic episodes. This dual positioning allows Venture Life to serve both wellness and medical markets, diversifying revenue streams.

These categories benefit from secular trends including rising diabetes prevalence, increased health consciousness, and mainstream recognition of stable blood sugar importance. The product ranges cater to consumer wellness and pharmacy-recommended medical support, broadening market reach.

Health & Her Hormonal Lifecycle Support Innovation

The Health & Her range addresses hormonal health for women across menstruation, perimenopause, menopause, and post-menopausal stages. This segment has grown substantially due to increased awareness, reduced stigma, and recognition of quality-of-life benefits from appropriate support products.

Hormonal health products command premium valuations reflecting clinical validation and consumer willingness to invest. Health & Her complements Balance Activ, creating a comprehensive women’s health offering across lifecycle stages. This enables integrated solutions for retailers and pharmacists and fosters long-term customer relationships.

Global Distribution Strategy and Retail Channels

Venture Life employs a differentiated distribution strategy tailored to market maturity and logistics. In core markets—the UK, Ireland, and USA—the company supplies retailers directly, enhancing margin capture, control over placement, and responsiveness to demand.

In other international markets, established distributors manage inventory, retailer relations, logistics, and marketing. This reduces capital needs and operational complexity while leveraging local expertise. The omnichannel approach includes direct e-commerce, pharmacy networks, health and beauty retailers, and grocery multiples, aligning with evolving consumer purchasing preferences and supporting broad market penetration.

Share Price and Valuation Insights

The repurchase price of 69.30 pence per share on 24 July 2026 offers insight into the company’s valuation at that time. Historical share performance, peer valuations, and financial metrics provide context for assessing whether the buyback price reflects value creation. Buybacks at lower valuation multiples may indicate effective capital deployment; those at higher multiples could suggest alternative uses of capital might be preferable.

The immediate share price impact was not publicly evident. Investors may monitor subsequent trading to evaluate market reaction to the buyback and capital allocation decisions. The total cost of this repurchase tranche—46,716 shares at 69.30 pence each—was approximately £32,354 before costs, representing a meaningful but modest capital deployment. The board’s decision to proceed likely reflects confidence in valuation and belief that share repurchase is the optimal capital use relative to alternatives.